Bowman & Co S.C. Sells 322 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bowman & Co S.C. trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,934 shares of the medical research company’s stock after selling 322 shares during the quarter. Bowman & Co S.C.’s holdings in Edwards Lifesciences were worth $949,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Riverview Trust Co acquired a new position in Edwards Lifesciences in the 1st quarter valued at approximately $34,000. DSM Capital Partners LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $34,000. Rise Advisors LLC increased its position in Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 265 shares during the period. Finally, Pingora Partners LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $38,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EW. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday, June 18th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Oppenheimer increased their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Finally, Piper Sandler increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $95.06.

Edwards Lifesciences Stock Up 0.5 %

Edwards Lifesciences stock opened at $91.56 on Thursday. The firm’s fifty day moving average price is $87.50 and its two-hundred day moving average price is $84.95. The firm has a market capitalization of $55.17 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 3.33 and a beta of 1.11. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the sale, the director now owns 4,486 shares of the company’s stock, valued at approximately $414,596.12. The disclosure for this sale can be found here. Insiders sold a total of 127,104 shares of company stock worth $11,267,464 over the last quarter. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.